Reasons for and effectiveness of switching back to originator infliximab after a prior switch to CT-P13 biosimilar

被引：0
|
作者：
Mahmmod, S. [1 ]
Schultheiss, J. P. D. [1 ]
Tan, A. C. I. T. L. [2 ]
Lutgens, M. W. M. D. [3 ]
Gilissen, L. P. L. [4 ]
Mahmmod, N. [5 ]
van der Meulen-de Jong, A. E. [6 ]
Dijkstra, G. [7 ]
van Bodegraven, A. A. [8 ]
Oldenburg, B. [1 ]
Fidder, H. H. [1 ]
机构：
[1] UMC Utrecht, Dept Gastroenterol & Hepatol, Utrecht, Netherlands
[2] Canisius Wilhelmina Ziekenhuis, Dept Gastroenterol & Hepatol, Nijmegen, Netherlands
[3] Elisabeth TweeSteden Ziekenhuis, Dept Gastroenterol & Hepatol, Tilburg, Netherlands
[4] Catharina Hosp, Dept Gastroenterol & Hepatol, Eindhoven, Netherlands
[5] St Antonius Hosp, Dept Gastroenterol & Hepatol, Nieuwegein, Netherlands
[6] Leiden UMC, Dept Gastroenterol & Hepatol, Leiden, Netherlands
[7] Univ Med Ctr Groningen, Dept Gastroenterol & Hepatol, Groningen, Netherlands
[8] Zuyderland Ziekenhuis, Dept Gastroenterol & Hepatol, Sittard, Netherlands
来源：
JOURNAL OF CROHNS & COLITIS | 2020年 / 14卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
P326
引用
收藏
页码：S316 / S317
页数：2
相关论文
共 50 条
  • [31] Infliximab biosimilar CT-P13 for inflammatory bowel disease
    Bonovas, Stefanos
    Peyrin-Biroulet, Laurent
    Danese, Silvio
    LANCET GASTROENTEROLOGY & HEPATOLOGY, 2018, 3 (06): : 373 - 375
  • [32] FREQUENCY AND REASONS FOR SWITCHING BACK TO BIOLOGIC ORIGINATOR FOLLOWING INITIAL SWITCH TO BIOLOGIC BIOSIMILAR
    Davies, Rebecca
    Kearsley-Fleet, Lianne
    Lunt, Mark
    Watson, Kath
    Hyrich, Kimme
    ANNALS OF THE RHEUMATIC DISEASES, 2019, 78 : 1141 - 1141
  • [33] Unchanged infliximab serum concentrations after switching from the originator infliximab to the biosimilar CT-P13 in patients with quiescent inflammatory bowel disease: Results from a prospective study (SECURE)
    Strik, A.
    van de Vrie, W.
    Bloemsaat-Minekus, J.
    Nurmohamed, M.
    Bossuyt, P.
    Bodelier, A.
    Rispens, T.
    van Megen, Y.
    D'Haens, G.
    JOURNAL OF CROHNS & COLITIS, 2018, 12 : S477 - S478
  • [34] FREQUENCY AND REASONS FOR SWITCHING BACK TO ETANERCEPT ORIGINATOR FOLLOWING INITIAL SWITCH TO ETANERCEPT BIOSIMILAR
    Davies, Rebecca
    Kearsley-Fleet, Lianne
    Lunt, Mark
    Watson, Kath D.
    Hyrich, Kimme L.
    RHEUMATOLOGY, 2019, 58
  • [35] Outcome of Reverse Switching From CT-P13 to Originator Infliximab in Patients With Inflammatory Bowel Disease
    Mahmmod, Shaden
    Schultheiss, Johannes P. D.
    van Bodegraven, Ad A.
    Dijkstra, Gerard
    Gilissen, Lennard P. L.
    Hoentjen, Frank
    Lutgens, Maurice W. M. D.
    Mahmmod, Nofel
    Van der Meulen-de Jong, Andrea E.
    Smits, Lisa J. T.
    Tan, Adriaan C. I. T. L.
    Oldenburg, Bas
    Fidder, Herma H.
    INFLAMMATORY BOWEL DISEASES, 2021, 27 (12) : 1954 - 1962
  • [36] Switching from originator infliximab to CT-P13: single-centre experience from the UK
    Bhandare, A. P.
    Crooks, B.
    Nigam, G. B.
    Limdi, J. K.
    JOURNAL OF CROHNS & COLITIS, 2019, 13 : S270 - S271
  • [37] Efficacy and Safety of CT-P13 (Infliximab Biosimilar) Over Two Years in Patients with Rheumatoid Arthritis: Comparison Between Continued CT-P13 and Switching from Infliximab to CT-P13.
    不详
    ARTHRITIS AND RHEUMATISM, 2013, 65 (12): : 3319 - 3319
  • [38] Switching from IFX originator to biosimilar CT-P13 does not impact effectiveness,safety and immunogenicity in a large cohort of IBD patients
    Pugliese, Daniela
    Guidi, Luisa
    Privitera, Giuseppe
    Bertani, Lorenzo
    Tolusso, Barbara
    Papparella, Luigi Giovanni
    Maltinti, Simona
    Di Mario, Clara
    Onali, Sara
    Ceccarelli, Linda
    Rapaccini, Gian Lodovico
    Scaldaferri, Franco
    Gremese, Elisa
    Gasbarrini, Antonio
    Costa, Francesco
    Armuzzi, Alessandro
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2021, 21 (01) : 97 - 104
  • [39] The effectiveness and safety of infliximab compared with biosimilar CT-P13, in 3112 patients with ulcerative colitis
    Meyer, Antoine
    Rudant, Jeremie
    Drouin, Jerome
    Coste, Joel
    Carbonnel, Franck
    Weill, Alain
    ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2019, 50 (03) : 269 - 277
  • [40] Infliximab biosimilar CT-P13 is interchangeable with its originator for patients with inflammatory bowel disease in real world practice
    Nakagawa, Tomoo
    Kobayashi, Taku
    Nishikawa, Kiyohiro
    Yamada, Fumika
    Asai, Satoshi
    Sameshima, Yulcinori
    Suzuki, Yasuo
    Watanabe, Mamoru
    Hibi, Toshifumi
    INTESTINAL RESEARCH, 2019, 17 (04) : 504 - 515
12345